论文部分内容阅读
目的探讨思密达+利巴韦林保留灌肠治疗婴幼儿轮状病毒性肠炎的疗效。方法将200例轮状病毒性肠炎患儿随机分为对照组、思密达口服组、思密达+利巴韦林保留灌肠组及利巴韦林组,在对照组常规治疗的基础上,思密达口服组给予思密达口服;思密达+利巴韦林灌肠组将思密达3 g+利巴韦林10~15 mg.kg/d-1溶于15 mL生理盐水保留灌肠,1次/d,连用3 d;利巴韦林组将利巴韦林10~15 mg.kg/d-1溶于5%葡萄糖溶液中静脉滴注,1次/d;观察各组发热、呕吐、腹泻、脱水等临床表现消失时间,并比较疗效。结果治疗72 h后对照组、思密达口服组,思密达+利巴韦林保留灌肠组及利巴韦林组总有效率分别为59.6%、73.9%、91.4%及65.9%。其中,思密达+利巴韦林保留灌肠组总有效率均较其他3组高,差异有统计学意义(P<0.01或P<0.05)。思密达+利巴韦林保留灌肠可明显缩短患儿退热、止吐、止泻及脱水纠正时间。结论在常规治疗基础上配合思密达+利巴韦林保留灌肠治疗婴幼儿轮状病毒性肠炎比常规治疗及常规治疗配合口服思密达或静脉滴注利巴韦林效果好。
Objective To investigate the efficacy of Smecta + ribavirin retention enema in the treatment of infantile rotavirus enteritis. Methods 200 children with rotavirus enteritis were randomly divided into the control group, the Smecta oral group, the Smecta + ribavirin retention enema group and the ribavirin group. On the basis of routine treatment in the control group, Smecta oral group given oral Smecta; Smecta + ribavirin enema group Smectite 3 g + ribavirin 10 ~ 15 mg.kg/d-1 dissolved in 15 mL saline retention enema, 1 / d, once every 3 d; ribavirin group ribavirin 10 ~ 15 mg.kg/d-1 dissolved in 5% glucose solution, intravenous infusion, 1 / d; observed the fever in each group, Vomiting, diarrhea, dehydration and other clinical manifestations disappeared, and more effective. Results After 72 hours of treatment, the total effective rates of the control group, the Smecta oral group, the Smecta + ribavirin retention enema group and the ribavirin group were 59.6%, 73.9%, 91.4% and 65.9%, respectively. Among them, the total effective rate of the Smecta + ribavirin retention enema group was higher than the other three groups, the difference was statistically significant (P <0.01 or P <0.05). Smecta + ribavirin retention enema can significantly reduce the children fever, antiemetic, antidiarrheal and dehydration correction time. Conclusion The treatment of infantile rotavirus enteritis with Smecta + ribavirin on the basis of routine treatment is better than routine treatment and conventional treatment with oral metmin or intravenous infusion of ribavirin.